Keros Therapeutics Inc
NASDAQ:KROS

Watchlist Manager
Keros Therapeutics Inc Logo
Keros Therapeutics Inc
NASDAQ:KROS
Watchlist
Price: 13.66 USD 0.74% Market Closed
Market Cap: 554.9m USD

Intrinsic Value

KROS's intrinsic value estimate is unreliable because it is based only on its multiples and doesn't use a DCF valuation.

The intrinsic value of one KROS stock under the Base Case scenario is 2.73 USD. Compared to the current market price of 13.66 USD, Keros Therapeutics Inc is Overvalued by 80%.

The Intrinsic Value is calculated as the average of DCF and Relative values:

KROS Intrinsic Value
2.73 USD
Overvaluation 80%
Intrinsic Value
Price
Base Case Scenario

Valuation History
Keros Therapeutics Inc

Valuation History Unavailable

Historical valuation for KROS cannot be conducted due to limitations such as insufficient data or other constraints.

Valuation In Progress...
Valuation In Progress...
0%
Compare KROS to

Fundamental Analysis

Company Overview
Loading...
Business Segments
Loading...
Management
Loading...
Contacts
Loading...
How do you feel about KROS?
Bearish
Neutral
Bullish
AI Assistant
AI Assistant
Ask me anything about Keros Therapeutics Inc
Financials
Annual
Quarterly
TTM

Balance Sheet Decomposition
Keros Therapeutics Inc

Current Assets 759.5m
Cash & Short-Term Investments 720.5m
Receivables 17.3m
Other Current Assets 21.7m
Non-Current Assets 25.1m
PP&E 23.1m
Other Non-Current Assets 1.9m
Efficiency

Free Cash Flow Analysis
Keros Therapeutics Inc

Last Value
3-Years Average
FCF Margin
Conversion Rate

Earnings Waterfall
Keros Therapeutics Inc

Revenue
214.7m USD
Operating Expenses
-225m USD
Operating Income
-10.3m USD
Other Expenses
14.5m USD
Net Income
4.2m USD
Fundamental Scores

KROS Profitability Score
Profitability Due Diligence

Keros Therapeutics Inc's profitability score is 38/100. The higher the profitability score, the more profitable the company is.

Exceptional 3-Years Revenue Growth
Exceptional Revenue Growth Forecast
Exceptional 1-Year Revenue Growth
ROE is Increasing
38/100
Profitability
Score

Keros Therapeutics Inc's profitability score is 38/100. The higher the profitability score, the more profitable the company is.

KROS Solvency Score
Solvency Due Diligence

Keros Therapeutics Inc's solvency score is 76/100. The higher the solvency score, the more solvent the company is.

Short-Term Solvency
Long-Term Solvency
Low D/E
High Altman Z-Score
76/100
Solvency
Score

Keros Therapeutics Inc's solvency score is 76/100. The higher the solvency score, the more solvent the company is.

Wall St
Price Targets

KROS Price Targets Summary
Keros Therapeutics Inc

Wall Street analysts forecast KROS stock price to rise over the next 12 months.

According to Wall Street analysts, the average 1-year price target for KROS is 26.07 USD with a low forecast of 15.15 USD and a high forecast of 36.75 USD.

Lowest
Price Target
15.15 USD
11% Upside
Average
Price Target
26.07 USD
91% Upside
Highest
Price Target
36.75 USD
169% Upside
View Analyst Estimates
View Analyst Estimates

Dividends

Keros Therapeutics Inc
does not pay dividends
Shareholder Yield

Current shareholder yield for KROS is .

Shareholder yield represents the total return a company provides to its shareholders, calculated as the sum of dividend yield, buyback yield, and debt paydown yield. What is shareholder yield?

Shareholder Yield
Dividend Yield
No dividends
Buyback Yield
Lowest
Average
Highest
Debt Paydown Yield
Lowest
Average
Highest

Competitive Landscape

Company Market Cap Intrinsic Valuation Profitability Solvency Price Change
1Y 3Y 5Y

Ownership

KROS Insider Trading
Buy and sell transactions by insiders

What is the Intrinsic Value of one KROS stock?

The intrinsic value of one KROS stock under the Base Case scenario is 2.73 USD.

Is KROS stock undervalued or overvalued?

Compared to the current market price of 13.66 USD, Keros Therapeutics Inc is Overvalued by 80%.

Back to Top